Aurobindo Pharmaceutical is recalling nearly 5 lakh bottles of Valsartan, a common drug used to treat blood pressure, sold in the United States. The US Food and Drug Administration found traces of NDEA in the medicines. NDEA has been identified as a possible carcinogenic by the International Agency For Research On Cancer. According to the drug authority, the level of the cancer-causing chemical was small and may lead to temporary adverse health side-effects if consumed. However, the FDA also shared that some versions of valsartan contained trace amounts of the carcinogen for about four years before regulators detected the impurity in July 2018.